TERIFLUNOMIDE

BUSHRA
HISTORY
• Teriflunomide is an oral therapy developed for the treatment of relapsing forms of multiple
sclerosis (MS).
• It was first approved by the U.S. Food and Drug Administration (FDA) in 2012.

• Teriflunomide is a part of the class of drugs known as disease-modifying therapies (DMTs) for
MS
MECHANISM+EFFECTIVENESS
• Teriflunomide works by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH).

• DHODH is involved in the synthesis of pyrimidine, an essential component of DNA and RNA.

• By inhibiting DHODH, Teriflunomide reduces the production of activated immune cells,

particularly T cells, which are involved in the inflammatory response in MS.
• Clinical trials have shown that Teriflunomide reduces the frequency of relapses and slows the
progression of disability in patients with relapsing forms of MS.
• It has been demonstrated to decrease relapse rates by around 30% compared to a placebo
A D M I N I S T R AT I O N S I D E E F F E C T S
• Teriflunomide is administered orally in the form of tablets and the recommended dosage is
usually once daily.
• Common side effects of Teriflunomide include diarrhoea, nausea, hair thinning, and increased
liver enzyme levels.
• Rare but serious side effects may include liver problems and a decrease in the number of white
blood cells.
• It is not recommended for individuals with severe liver problems or those who are pregnant or
planning to become pregnant due to potential risks to the foetus
F U N FA C T
• Teriflunomide is derived from leflunomide, which was originally developed as a medication for
rheumatoid arthritis. The success of leflunomide in reducing immune activity led to the
exploration of its potential for treating multiple sclerosis, resulting in the development of
Teriflunomide specifically for MS